Have a personal or library account? Click to login

Renal Cell Carcinoma – How Can We Predict its Outcomes in Clinical Practice?

Open Access
|Sep 2013

References

  1. 1. Bedke J, Buse S, Pritsch M, et al. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences // BJU International, 2009; 103(10):1349-1354
  2. 2. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma // Am J Surg Pathol, 2003; 27:612-624
  3. 3. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy // Cancer, 2007; 110:543-550
  4. 4. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? // Cancer, 2010; 116:3378-3388
  5. 5. de Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer // Eur J Cancer, 2009; 45:765-773
  6. 6. Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence // J Clin Oncol, 2006; 24(19):3101-3106
  7. 7. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma // Cancer Res, 1988; 48:7310-7313
  8. 8. Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941 // J Urol, 2007; 178:1901-1905
  9. 9. Escudier B, Kataja V; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol, 2010; 21(5):137-139
  10. 10. European Cancer Observatory (ECO) // eco.iarc.fr
  11. 11. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma // Oncologist, 2011; 16(2):4-13
  12. 12. Flanigan RC, Salmon SE, Blumenstain BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer // N Engl J Med, 2001; 345:1655
  13. 13. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score // J Urol, 2002; 168:2395-2400
  14. 14. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study // J Clin Oncol, 2009; 27:5794
  15. 15. Hudes G, Carducci M, Tomczk P, et al. Temsirolimus, interferon alfa, or both for advanced renal‐cell carcinoma // N Engl J Med, 2007; 356, 2271-228110.1056/NEJMoa06683817538086
  16. 16. Ii mura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score // J Urol, 2009; 181(3):1004-1012
  17. 17. Is barn H, Karakiewicz PI. Predicting cancer-control outcomes in patients with renal cell carcinoma // Curr Opin Urol, 2009; 19(3):247-257
  18. 18. Je ldres C, Karakiewicz PI, Suardi N, et al. Conditional survival predictions after nephrectomy for renal cell carcinoma // J Urol, 2009; 182(6):2607-2612
  19. 19. Je ppesen AN, Jensen HK, Donskov F, et al. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma // Br J Cancer, 2010; 102:867
  20. 20. Ka volius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma // J Clin Oncol, 1998; 16:2261-2266
  21. 21. Ki m HL, Belldegrun AS, Freitas DG, et al. A Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis // J Urol, 2003; 170:1742-1746
  22. 22. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma // J Urol, 2005; 173(5):1496-1501
  23. 23. Kuti kov A, Egleston BL, et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram // J Clin Oncol, 2010; 28(2):311-317
  24. 24. Kuti kov A, Smaldone MC, Egleston, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score // Eur Urol, 2011; 60(2):241-248
  25. 25. Lee CT, Katz J, Fearn PA, et al. Mode of presentation of renal cell carcinoma provides prognostic information // Urol Oncol, 2002; 7:135-140
  26. 26. Lee LS, Tan MH. Predictive models for the practical management of renal cell carcinoma// Nat Rev Urol, 2012; 9(2):73-84
  27. 27. Leib ovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials // J Urol, 2005; 174:1759-176328. Ljun gberg B, Cowan NC B, Cowan NC, et al. EAU guidelines on renal cell carcinoma: the 2010 update // Eur Urol, 2010; 58:398-406
  28. 29. Mano la J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group // Clin Cancer Res, 2011; 17(16):5443-5450
  29. 30. Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors // Cancer, 2000; 89:604-614
  30. 31. Motz er RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. Version 2.2012 // J Natl Compr Canc Netw, 2009; 7:618-30
  31. 32. Motz er RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan - Kettering Cancer Center experience // Clin Cancer Res, 2004; 10:6302-6303
  32. 33. Motz er RJ, Bacik J, Murphy BA, et al. Interferon- alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma // J Clin Oncol, 2002; 20:289-296
  33. 34. Motz er RJ, Bukowski RM, Figlin, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma // Cancer, 2008; 113:1552-1558
  34. 35. Negr ier S, Gomez F, Douillard JY, et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie // World J Urol, 2005; 23:161-165
  35. 36. Park er AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma // Cancer, 2009; 115:2092-2103
  36. 37. Sorb ellini M, Kattan MW, Snyder M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma // J Urol, 2005; 173:48-51
  37. 38. Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review// Eur Urol, 2011; 60(4):644-661
  38. 39. Tan MH, Choong CV, Chia KS, et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma // Cancer, 2011; 117:5314-5324
  39. 40. Tang PA, Vickers MM, Heng DY, Heng YC. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far // Hematol Oncol Clin North Am, 2011; 25(4):871-891
  40. 41. Tapp er H, Klein H, Rubenstein W, et al. Recurrent renal cell carcinoma after 45 years // Clin Imaging, 1997; 21(4):273-275
  41. 42. Terr one C, Cracco F, Porpiglia F, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma // Eur Urol, 2006; 49(2):324-31.
  42. 43. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma // World J Urol, 2010; 28(3):319-327
  43. 44. Wu Y, Fu X, Xiaoli Z, et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis // J Cancer Res Clin Oncol, 2011; 137(5):887-896
  44. 45. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma // J Clin Oncol, 2002; 20:4559-4566
DOI: https://doi.org/10.2478/chilat-2013-0012 | Journal eISSN: 2199-5737 | Journal ISSN: 1407-981X
Language: English
Page range: 63 - 70
Published on: Sep 5, 2013
Published by: Riga Stradins University
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year

© 2013 Ieva Vaivode, Vilnis Lietuvietis, Alinta Hegmane, Iveta Kudaba, published by Riga Stradins University
This work is licensed under the Creative Commons License.